Inositec AG

Swiss Biotech Association

Member

Inositec AG is developing first-in-class treatments for soft tissue calcification disorders based on its proprietary Inositune™ platform of inositol phosphate (IP6) analogs. The company’s lead programs address vascular and renal calcification disorders, including orphan indications. The company's current focus is on developing the cardiovascular calcification inhibitor INS-3001 as a first-in-class treatment for aortic valve stenosis. Inositec was founded in December 2015 as a spin-off of ETH Zurich.

Location

Technoparkstrasse 1, 8005 Zürich, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2015
Number of employees in Switzerland

1-9

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

Labatec Pharma SA

Labatec is a privately owned Swiss-based pharmaceutical company with more than 50 years of experience in delivering high quality products to the European and Emerging Markets. Covering both the hospital and retail sectors, we have a portfolio of over 65 products and a growing geographic footprint.
Meyrin

Member

GlycoEra AG

GlycoEra leverages its control over natural glycan-mediated pathways to advance novel drugs using its propriety platform, the CustumGlycan Platform. GlycoEra develops first in class therapeutics in inflammatory disease, autoimmune disorder and immuno-oncology indications.
8952 Schlieren

Member

JFG Life Sciences Stiftung der Universität Basel

Our foundation supports the transfer of innovation from medical research to industry, in particular through young entrepreneurship in Switzerland. We invest in companies in Switzerland or abroad that are active in the field of life sciences. We value strong founding teams and high-quality science.
4051 Basel

Member